Platinum-resistant Ovarian Cancer Withdrawn Phase 2 Trials for Topotecan (DB01030)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

IndicationStatusPhase
DBCOND0068919 (Platinum-resistant Ovarian Cancer)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05736952Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian CancerTreatment